Royalty Pharma plc (MUN:RPD)
Germany · Delayed Price · Currency is EUR | Market Cap | 20.56B +64.8% |
| Revenue (ttm) | 2.12B +7.8% |
| Net Income | 716.64M -24.4% |
| EPS | 1.65 -22.4% |
| Shares Out | n/a |
| PE Ratio | 28.69 |
| Forward PE | 8.12 |
| Dividend | 0.78 (1.64%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | n/a |
| Open | 47.11 |
| Previous Close | 47.49 |
| Day's Range | 47.11 - 47.11 |
| 52-Week Range | 30.41 - 47.11 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune ... [Read more]
Financial Performance
In 2025, Royalty Pharma's revenue was $2.38 billion, an increase of 5.06% compared to the previous year's $2.26 billion. Earnings were $770.95 million, a decrease of -10.25%.
Financial numbers in USD Financial StatementsNews
Royalty Pharma Transcript: RBC Capital Markets Global Healthcare Conference 2026
Royalty financing is expanding rapidly in biopharma, with flexible deal structures and a focus on high-impact products. The company is leveraging its scale, low cost of capital, and global reach to drive growth, targeting $2–2.5 billion in annual investments and exploring new markets like China.
Royalty Pharma Transcript: Bank of America Global Healthcare Conference 2026
The business is experiencing robust growth in royalty financing, driven by large pharma partnerships, geographic expansion, and a maturing pipeline. Operational scaling, a unique capital structure, and a diversified portfolio support resilience against competition and policy uncertainty.
Royalty Pharma Slides: Corporate presentation
Royalty Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Royalty Pharma to present at upcoming investor conferences
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Royalty Pharma price target raised to $64 from $63 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Royalty Pharma (RPRX) to $64 from $63 and keeps an Overweight rating on the shares.
Royalty Pharma price target raised to $58 from $50 at JPMorgan
JPMorgan raised the firm’s price target on Royalty Pharma (RPRX) to $58 from $50 and keeps an Overweight rating on the shares.
Royalty Pharma price target raised to $66 from $50 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $50 and keeps a Buy rating on the shares. The firm views the company’s…
Royalty Pharma Earnings Call Transcript: Q1 2026
Delivered double-digit growth in portfolio and royalty receipts in Q1 2026, raised full-year guidance, and expanded R&D co-funding and global capabilities. Maintained strong returns and financial flexibility, with significant new deals and positive clinical milestones.
Royalty Pharma Earnings release: Q1 2026
Royalty Pharma released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Royalty Pharma Slides: Q1 2026
Royalty Pharma has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Royalty Pharma Quarterly report: Q1 2026
Royalty Pharma has published its Q1 2026 quarterly earnings report on May 6, 2026.
Royalty Pharma reports first quarter 2026 results
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected t...
An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market
The drug royalty business thrives on a bet that an approved biologic will keep printing money along a predictable schedule. Patent expires here, biosimilar enters there, revenue declines at roughly th...
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in transl...
Royalty Pharma price target raised to $57 from $51 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Royalty Pharma (RPRX) to $57 from $51 and keeps a Buy rating on the shares. Royalty Pharma has continued to…
Royalty Pharma Declares Second Quarter 2026 Dividend
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ord...
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. fi...
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Royalty Pharma (RPRX) to $63 from $61 and keeps an Overweight rating on the shares. The firm adjusted models…
Royalty Pharma Proxy statement: Proxy filing
Royalty Pharma filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Royalty Pharma Proxy statement: Proxy filing
Royalty Pharma filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Royalty Pharma and J&J partner to develop autoimmune treatment
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
Royalty Pharma (RPRX) announced a research and development co-funding agreement with Johnson & Johnson (JNJ) for a total of $500M in 2026 and 2027 to advance the development of JNJ-4804,…
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million ...
Royalty Pharma Slides: Corporate presentation
Royalty Pharma has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead ...